Parihar Ashwin Singh, Pant Niharika, Heidari Pedram, Fong Lawrence, Iravani Amir
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
J Nucl Med. 2025 Jun 2;66(6):839-847. doi: 10.2967/jnumed.124.268289.
This review explores the role of PET in imaging immune activation, particularly in oncology. F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique response patterns as well as immune-related adverse events. However, because of the limited specificity of F-FDG, newer PET radiopharmaceuticals targeting specific cellular or subcellular components of the immune system have been developed that can provide more precise information. The development of immune-specific PET radiopharmaceuticals offers significant potential for improving immune monitoring in both clinical practice and research.
本综述探讨了正电子发射断层扫描（PET）在免疫激活成像中的作用，尤其是在肿瘤学领域。氟代脱氧葡萄糖（F-FDG）被广泛用于评估免疫治疗的疗效，并且能够显示独特的反应模式以及免疫相关不良事件。然而，由于F-FDG的特异性有限，已开发出针对免疫系统特定细胞或亚细胞成分的新型PET放射性药物，这些药物可以提供更精确的信息。免疫特异性PET放射性药物的开发为改善临床实践和研究中的免疫监测提供了巨大潜力。
